April 20, 2017 The presentation includes a brief corporate update from Leo Ehrlich, Chief Executive Officer, and a clinical overview by Dr. Arthur Bertolino, MD, PHD, MBA, President and Chief Medical Officer, with particular emphasis given to Brilacidin interim trial results in Inflammatory Bowel Disease and Oral Mucositis.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.